Veliparib (ABT-888)

目录号:S1004 别名: NSC 737664

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888)是一种有效的PARP1PARP2抑制剂,无细胞试验中Ki分别为5.2 nM和2.9 nM,对SIRT2没有活性。Phase 3。

规格 价格 库存 购买数量  
In DMSO RMB 1277.12 现货
RMB 973.01 现货
RMB 3010.72 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献119篇:

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述 Veliparib (ABT-888)是一种有效的PARP1PARP2抑制剂,无细胞试验中Ki分别为5.2 nM和2.9 nM,对SIRT2没有活性。Phase 3。
特性 ABT-888增强常见癌症疗法的效果,比如放射疗法和烷基化剂。
靶点
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
体外研究

ABT-888有效抑制PARP,作用于PARP-1和PARP-2时Ki值分别为5.2和2.9 nM。ABT-888降低肺癌H460细胞中克隆基因的存活率,且抑制DNA修复。[1]ABT-888抑制C41细胞,EC50为2 nM。[2] ABT-888和放射物联用减少肿瘤血管的形成。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 NIW3bFdMcW6jc3WgRZN{[Xl? NImwTYQ{OCCvaX6= Ml\yTY5pcWKrdHnvckBw\iCSQWLQNUB4cXSqIFXDOVAhd2ZiMD6wNFIh|ryP NEf5UJIyQTh6OEe2NC=>
Jurkat NV3FWppUU2mwYYPlJGF{e2G7 NVTWXYtlQTZiaB?= MUTEUXNQ Ml\YTY5pcWKrdHnvckBw\iCSQWLQNUBie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gZ4VtdCC4aXHibYxqfHlid3n0bEBGSzVyIH;mJFMh|ryP M1PuZVI{QDVyMUm5
Capan1 M4HBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkGxO|IhcA>? NXnjSZRCTE2VTx?= MVLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFLSR2EzKGenbnWgcZV1[XSnZDDoeY1idiCFYYDhclEh[2WubIOge4l1cCCLQ{WwJI9nKDN7Lkeg{txO NXXvNWl5OjR|OUizPFM>
DT40 MX;DfZRwfG:6aXOgRZN{[Xl? MnjsO|IhcA>? NXPueYhuTE2VTx?= NHOzXphEgXSxdH;4bYNqfHliYXfhbY5{fCClaHnjb4VvKEKUQ1GyMYRm\mmlaXXueEBFXDRyIHPlcIx{ NEfEV5YzPDl{MkW4Oy=>
ML-1 M3faUGFxd3C2b4TpZ{BCe3OjeR?= M2izXVIvPSEQvF2= MXeyOEBp M4X0dGROW09? MVzTfY5memerc4TpZ4FtdHliZX7oZY5k\XNiVGLBTWwucW6mdXPl[EBieG:ydH;zbZMhcW5iTVytNUBk\Wyucx?= MoLINlQ5QTVzM{W=
HCT-116 M{ize2tqdmG|ZTDBd5NigQ>? NYLRZW5qOC53IN88US=> MXKyOEBp NYfGblZVWEGUUDDhZ5Rqfmm2eTDk[YNz\WG|ZYO= M3HaZVI{ODV2MkGz
UM-SCC1 NIHqTm5EgXSxdH;4bYMhSXO|YYm= M{nhW|ExKM7:TR?= M4XhS|I1KGh? M{TRUXJm\HWlZYOgeIhmKGOnbHygeoli[mmuaYT5 Mn\VNlE6OTJ4MkC=
FaDu MXPDfZRwfG:6aXOgRZN{[Xl? NHHPXI4yOCEQvF2= NEC3O5EzPCCq M37veHJm\HWlZYOgeIhmKGOnbHygeoli[mmuaYT5 NYLYOWM2OjF7MUK2NlA>
PC-3 NVH2VZlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PBOVExKM7:TR?= NYnDUWZSUW6mdXPld{BiKHOrZ37p[olk[W62IHnubIljcXSrb36gbY4h[2:ub375JIZwem2jdHnvcuKh MmK2NlE2PzF7MUK=
EoL-1-cell NGr5bFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrWRZN{UUN3ME2xMlA4QThizszN MmXUV2FPT0WU
NCI-SNU-5 NWnyV|l[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fDd2lEPTB;Mz6xNlg1OSEQvF2= MVjTRW5ITVJ?
BV-173 NI\icIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTVwNEW0NFkh|ryP MVnTRW5ITVJ?
HCC1806 NVvub5lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH3d|JKSzVyPUWuO|UyPzNizszN M4r3[HNCVkeHUh?=
COLO-680 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW0OoFKSzVyPU[uNlE1ODZizszN M37WfHNCVkeHUh?=
HCC2218 M3jLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTdwN{m3NFQh|ryP MXjTRW5ITVJ?
SK-MEL-24 Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne3TWM2OD15LkixPVI1KM7:TR?= MVHTRW5ITVJ?
NCI-H720 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWf5T3lSUUN3ME24MlQ{PjB|IN88US=> MY\TRW5ITVJ?
KASUMI-1 M4[3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrQTWM2OD16Lki5NlY3KM7:TR?= NYfzZVRkW0GQR1XS
HAL-01 NFLRWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PQOmlEPTB;OT64PFYzKM7:TR?= NUe1d2VjW0GQR1XS
CAL-33 NVzFdpI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjrS21KSzVyPUGwMlQ{PCEQvF2= NXXk[4pTW0GQR1XS
SK-MEL-1 NX[1eGVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF{LkS2OlMh|ryP MkW1V2FPT0WU
Ramos-2G6-4C10 NF:2VmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF{LkS3OVIh|ryP NUnhdmF2W0GQR1XS
KY821 Mk[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTHTWM2OD1zMj60PFUh|ryP M{PzbXNCVkeHUh?=
HEC-1 NWfpNZhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTF{LkmxPVYh|ryP NV;hWpc5W0GQR1XS
SK-NEP-1 NFXkeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MomxTWM2OD1zMz6xOlYh|ryP MYHTRW5ITVJ?
MN-60 M2\EbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTF|LkWzPFkh|ryP M37DUXNCVkeHUh?=
DU-145 MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXGV5pKSzVyPUGzMlkxPTNizszN MkmwV2FPT0WU
EW-3 NIPwb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr2b29KSzVyPUG0MlU2PjVizszN MU\TRW5ITVJ?
OS-RC-2 M3z3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF3Lkm1PFkh|ryP MVjTRW5ITVJ?
RPMI-8226 NWT6cpFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D0VmlEPTB;MU[uNlA1OiEQvF2= MlvVV2FPT0WU
ChaGo-K-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTtcHY1UUN3ME2xOk42OzJ3IN88US=> NGnRU5RUSU6JRWK=
DEL NGfSOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;VeItKSzVyPUG2MlY4OTdizszN M2Pv[XNCVkeHUh?=
GP5d M2nYUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTF5LkC1N{DPxE1? MWPTRW5ITVJ?
COLO-668 NYS0d|ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rWemlEPTB;MUeuOlI6PCEQvF2= MYHTRW5ITVJ?
H9 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{WwVmlEPTB;MUiuNlg{OyEQvF2= M1:3ZnNCVkeHUh?=
NKM-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG[2dZVKSzVyPUG4MlUyOTlizszN NFXTRpZUSU6JRWK=
KYSE-150 NEfMfVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjNTWM2OD1zOD65PVg3KM7:TR?= M2LSPHNCVkeHUh?=
Daoy MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHiUoptUUN3ME2xPU42PjR7IN88US=> MV3TRW5ITVJ?
ECC10 NHLHWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJyLke0OVUh|ryP MXnTRW5ITVJ?
A388 M{HnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXwTWM2OD1{MT65NFkyKM7:TR?= NIf3fYFUSU6JRWK=
MHH-NB-11 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUm0Zpo1UUN3ME2yN{4yOzZ|IN88US=> Mor1V2FPT0WU
HCC1937 NHjFVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XzNGlEPTB;MkSuO|Q3KM7:TR?= NVrGdIpCW0GQR1XS
TGBC11TKB MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLxTWM2OD1{NT62PFY{KM7:TR?= M1;OV3NCVkeHUh?=
CTV-1 NV7jRnVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17jbWlEPTB;MkWuPFk3QSEQvF2= NF;6T4FUSU6JRWK=
NCI-H2029 NH3sTXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PndmlEPTB;Mk[uOFI{QCEQvF2= NGLNSpdUSU6JRWK=
HLE M3qw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH31SXdKSzVyPUK3MlA2PCEQvF2= M3nXOnNCVkeHUh?=
NCI-H1693 M3[yeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvjTWM2OD1{Nz6yPFk5KM7:TR?= NIPl[WFUSU6JRWK=
HCC70 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LUTGlEPTB;MkeuO|I1PiEQvF2= NWTGUmVwW0GQR1XS
BEN MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfGTWM2OD1{Nz65OVY3KM7:TR?= M2K4V3NCVkeHUh?=
LB771 M{nqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PRdWlEPTB;MkiuPFM4OyEQvF2= MkL3V2FPT0WU
697 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWX1[4JEUUN3ME2yPU4xOjN3IN88US=> M3\1eXNCVkeHUh?=
LU-139 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\iTWM2OD1{OT6zO|Q5KM7:TR?= Mn;OV2FPT0WU
EW-13 NX\4Xo1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;5TWM2OD1{OT6zPFE1KM7:TR?= MVLTRW5ITVJ?
MOLT-13 M4PhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnISJJPUUN3ME2yPU4{QDF2IN88US=> MmjRV2FPT0WU
L-363 NHXoTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP2dYpKSzVyPUK5MlQ4QThizszN M1PJe3NCVkeHUh?=
EM-2 MlrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJ7LkS5NFEh|ryP NIrGb5RUSU6JRWK=
RS4-11 NUjhOVM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXPNFdKSzVyPUOwMlQzPDFizszN MWXTRW5ITVJ?
A2780 NXzvbVJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHwTWM2OD1|MD63OFU4KM7:TR?= MUfTRW5ITVJ?
KU812 NFjFXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnlRY8xUUN3ME2zNk4{PjR{IN88US=> NUjsfVh5W0GQR1XS
COLO-684 M4fEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTmempKSzVyPUOzMlM2QTlizszN MlrPV2FPT0WU
MFE-280 M1[2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PQPGlEPTB;M{OuN|g5QSEQvF2= NWLyOGFGW0GQR1XS
KG-1 Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTN|Lk[wNFEh|ryP MV;TRW5ITVJ?
JVM-3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFywRpFKSzVyPUO1MlU5PjhizszN MX\TRW5ITVJ?
MV-4-11 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnzTWM2OD1|NT64OFk6KM7:TR?= NIC3[ZRUSU6JRWK=
LAMA-84 NGizR45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HGfGlEPTB;M{[uO|M1PSEQvF2= NYrKPZB5W0GQR1XS
MOLT-16 M4L0emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTN4Lkm1NkDPxE1? MoLVV2FPT0WU
H4 NUT1[3JoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD0TWM2OD1|Nz61Olch|ryP NIizNHdUSU6JRWK=
T47D MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q0W2lEPTB;M{euO|AyQCEQvF2= NYjXVVlrW0GQR1XS
CAL-54 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\hTWM2OD1|Nz65OlYh|ryP MnuyV2FPT0WU
SW982 NEfBN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jzUWlEPTB;M{iuNFk6QCEQvF2= MXrTRW5ITVJ?
IGROV-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f4fWlEPTB;M{muN|MxPCEQvF2= NH7nR4xUSU6JRWK=
NB14 NIWyWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TRZWlEPTB;NECuO|A{OSEQvF2= NX\KblJVW0GQR1XS
HCC1187 NHvrVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLOZppKSzVyPUSxMlI4PzFizszN NIj6WXlUSU6JRWK=
SBC-1 M2nPUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj5cGJiUUN3ME20NU4{ODZ|IN88US=> Mm[5V2FPT0WU
KARPAS-45 M3HZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfxTWM2OD12MT60PFE5KM7:TR?= M4\ZTXNCVkeHUh?=
MOLT-4 MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:yTWM2OD12Mj6yOVM5KM7:TR?= M4XuOHNCVkeHUh?=
JVM-2 M{TITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT2ZVBWUUN3ME20Nk46OjB5IN88US=> MYnTRW5ITVJ?
A4-Fuk MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHOTWM2OD12Mz61OlkyKM7:TR?= NVvwVnhZW0GQR1XS
MDA-MB-361 NYixTWl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTR|Lki0NVQh|ryP M2W2S3NCVkeHUh?=
BALL-1 NWnMeodzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7BZlFOUUN3ME20N{46PTN{IN88US=> M3jnSnNCVkeHUh?=
T98G NVKydXc{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXxTWM2OD12ND64OVE4KM7:TR?= MV\TRW5ITVJ?
Mo-T MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fCWmlEPTB;NEWuOlM5QSEQvF2= M4jwVnNCVkeHUh?=
MHH-PREB-1 M1HZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTR3Lke1PFUh|ryP MlHBV2FPT0WU
ALL-PO NIqzSW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDIdFVuUUN3ME20O{4{PzlzIN88US=> MkjPV2FPT0WU
NCI-H510A NUjS[Hg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT0OIJKSzVyPUS3MlkxOzRizszN M1HsTnNCVkeHUh?=
ML-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTR7Lke4OVYh|ryP Mof6V2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-STAT3 / STAT3 / p-AKT(S473) / p-AKT(T308) / p-ERK / p-p38; 

PubMed: 22678161     


Effects of AG-014699, AZD-2281, ABT-888, or BSI-201 on the phosphorylation status of Stat3, Akt, ERK, and p38 in MDA-MB-468, MDA-MB-231, and Cal-51 cells after 72 h of treatment

22678161
Immunofluorescence
HuR; 

PubMed: 28687616     


Immunofluorescent images of HuR (green) in MIA PaCa-2 cells treated with PARPi for 12hr. Nuclei were stained with DAPI. Magnification 40X.

BRCA1; 

PubMed: 21917757     


Effects of ABT-888 and/or bortezomib on BRCA1 and RAD51 foci formation. BRCA1 and RAD1 foci induced by ABT-888 were completely resolved in cells cotreated with bortezomib. Image acquisition was performed with an epifluorescence microscope (BX51; Olympus) and multispectral color camera (Nuance FX; CRi) with a 60× or 100× magnification lens and oil immersion.

28687616 21917757
Growth inhibition assay
Cell viability (TNBC cell lines); 

PubMed: 27880910     


BRCA-proficient TNBC cell lines were treated with veliparib in the absence and presence of dinaciclib, demonstrating reduced IC50 values in the presence of dinaciclib.

Cell viability (melanoma cells); 

PubMed: 29956724     


Dose-dependent inhibitory effect of ABT-888 on melanoma cell proliferation. Human melanoma cell lines were exposed to diluents (control; CTRL) or increasing concentrations of ABT-888 for 72 h and their viability was assessed by MTT assay. Absorbance was detected at 540 nm with a microplate reader and data were expressed as a percentage of the CTRL. Data are the means ± SD of 3 experiments performed in triplicate. Statistical significance was calculated against the CTRL (*P<0.05; **P<0.01).

27880910 29956724
体内研究 ABT-888推迟NCI-H460 移植瘤模型的肿瘤生长。ABT-888在B16F10 和9L 移植瘤模型中抑制PARP,从而增强temozolomide的抗癌活性。[1]ABT-888和其他细胞毒素药剂联用作用于MX-1移植瘤模型时显示出强抗癌效力。[2]在A375和 Colo829移植瘤模型中按肿瘤大小,每千克分别加3和12.5 mg ABT-888,可以看到肿瘤内95%以上PAR被抑制。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

体外PARP实验:

在含有50 mM Tris (pH 为8.0), 1 mM DTT,和 4 mM MgCl2的缓冲溶液中进行酶活性测定。PARP反应包含1.5 μM [3H]-NAD+ (1.6 μCi/mmol), 200 nM 生物素组蛋白 H1, 200 nM slDNA,及1 nM PARP-1或4 nM PARP-2酶。在加有100 μL 反应液的 96孔板上进行SPA检测。在50 μL含有PARP和DNA的2×酶液混合物中加入50 μL 2×NAD+基底混合物,反应开始。加入150 μL 1.5 mM 苯甲酰胺反应停止。170uL反应终止液转移到链霉亲和素包被的闪熔镀层上,温育1小时,用微型板块闪烁计数器计数。
细胞实验:[2]
- 合并
  • Cell lines: C41细胞
  • Concentrations: 10 μM 左右
  • Incubation Time: 0.5小时
  • Method: 在96孔板上用ABT-888处理C41细胞0.5小时。用1 mM H2O2破坏DNA10分钟,PARP被激活。用冰冻的PBS冲洗细胞,然后用预冷的甲醇/丙酮(按7:3比例混合)在−20oC下固定10 分钟。风干后,用PBS再溶解,然后用溶有5%脱脂奶粉的PBS- Tween封闭液(0.05%)在室温下阻断0.5小时。细胞和PAR抗体按1:50比例在封闭液中室温下温育1小时,然后用PBS-Tween-20冲洗5分钟,然后加入荧光素-5(6)-异硫氰酸酯 (FITC)-联用的二抗和1μg/mL DAPI封闭液中室温下温育1小时。PBS-Tween-20冲洗5分钟后,用荧光微型版计数器分析数据。
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 携带NCI-H460, H460, B16F10和9L移植瘤的C57BL/6鼠
  • Formulation: 在含0.9% NaCl溶液中配制,调节pH 为4.0
  • Dosages: 25或3.125 mg/kg
  • Administration: 口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 17 mg/mL (69.58 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
0.5% methylcellulose+0.2% Tween 80
5 mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 244.29
化学式

C13H16N4O

CAS号 912444-00-9
储存条件 粉状
溶于溶剂
别名 NSC 737664

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03044795 Withdrawn Drug: Veliparib Cancer University Medical Center Groningen|AbbVie|Dutch Cancer Society November 2019 Phase 2
NCT02723864 Recruiting Drug: Veliparib + VX-970 + Cisplatin Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2017 Phase 1
NCT02483104 Completed Drug: veliparib|Drug: carboplatin|Drug: paclitaxel Ovarian Cancer AbbVie July 2015 Phase 1
NCT01445522 Completed Drug: ABT-888|Drug: Cyclophosphamide Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 3 2008 Phase 1
NCT00649207 Completed Drug: ABT-888|Radiation: Whole Brain Radiation Therapy Brain Diseases|Brain Neoplasms|Central Nervous System Diseases|Neoplasm Metastasis|Nervous System Neoplasms AbbVie (prior sponsor Abbott)|AbbVie March 2008 Phase 1
NCT00553189 Completed Drug: ABT-888|Drug: Topotecan Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9 2007 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

相关PARP产品

Tags: 购买Veliparib (ABT-888) | Veliparib (ABT-888)供应商 | 采购Veliparib (ABT-888) | Veliparib (ABT-888)价格 | Veliparib (ABT-888)生产 | 订购Veliparib (ABT-888) | Veliparib (ABT-888)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID